Denali Therapeutics reports third quarter net loss of $126.9 million

Reuters11-07

Denali <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter net loss of $126.9 million

Denali Therapeutics Inc. reported a net loss of $126.9 million for the third quarter ended September 30, 2025, compared to a net loss of $107.2 million for the same period in 2024. Total research and development expenses were $102.0 million, up from $98.2 million in the prior year quarter, with increases driven by new operations at the company's large molecule manufacturing facility in Salt Lake City, Utah. The company highlighted continued engagement with the FDA regarding the tividenofusp alfa BLA review for MPS II and completed enrollment in the DNL126 Phase 1/2 study for MPS IIIA. Denali also submitted regulatory applications to begin clinical studies with DNL628 for Alzheimer's disease and DNL952 for Pompe disease. Leadership changes include Peter Chin, M.D., assuming the role of Acting Chief Medical Officer following the departure of Carole Ho, M.D.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001714899-25-000192), on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581017054?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581017054","market":"nz","top_or_hot":-1,"title":"Denali Therapeutics reports third quarter net loss of $126.9 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports third quarter net loss of $126.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNLI\">Denali Therapeutics Inc.</a> reported a net loss of $126.9 million for the third quarter ended September 30, 2025, compared to a net loss of $107.2 million for the same period in 2024. Total research and development expenses were $102.0 million, up from $98.2 million in the prior year quarter, with increases driven by new operations at the company's large molecule manufacturing facility in Salt Lake City, Utah. The company highlighted continued engagement with the FDA regarding the tividenofusp alfa BLA review for MPS II and completed enrollment in the DNL126 Phase 1/2 study for MPS IIIA. Denali also submitted regulatory applications to begin clinical studies with DNL628 for Alzheimer's disease and DNL952 for Pompe disease. Leadership changes include Peter Chin, M.D., assuming the role of Acting Chief Medical Officer following the departure of Carole Ho, M.D.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001714899-25-000192), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denali Therapeutics reports third quarter net loss of $126.9 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenali Therapeutics reports third quarter net loss of $126.9 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports third quarter net loss of $126.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNLI\">Denali Therapeutics Inc.</a> reported a net loss of $126.9 million for the third quarter ended September 30, 2025, compared to a net loss of $107.2 million for the same period in 2024. Total research and development expenses were $102.0 million, up from $98.2 million in the prior year quarter, with increases driven by new operations at the company's large molecule manufacturing facility in Salt Lake City, Utah. The company highlighted continued engagement with the FDA regarding the tividenofusp alfa BLA review for MPS II and completed enrollment in the DNL126 Phase 1/2 study for MPS IIIA. Denali also submitted regulatory applications to begin clinical studies with DNL628 for Alzheimer's disease and DNL952 for Pompe disease. Leadership changes include Peter Chin, M.D., assuming the role of Acting Chief Medical Officer following the departure of Carole Ho, M.D.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001714899-25-000192), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNLI","symbol_name":"Denali Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLBVYF7:1","article_id":"2581017054","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581017054","pubTimestamp":1762463185,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Denali Therapeutics Inc. reported a net loss of $126.9 million for the third quarter ended September 30, 2025, compared to a net loss of $107.2 million for the same period in 2024. Total research and development expenses were $102.0 million, up from $98.2 million in the prior year quarter, with increases driven by new operations at the company's large molecule manufacturing facility in Salt Lake City, Utah. The company highlighted continued engagement with the FDA regarding the tividenofusp alfa BLA review for MPS II and completed enrollment in the DNL126 Phase 1/2 study for MPS IIIA. Denali also submitted regulatory applications to begin clinical studies with DNL628 for Alzheimer's disease and DNL952 for Pompe disease. Leadership changes include Peter Chin, M.D., assuming the role of Acting Chief Medical Officer following the departure of Carole Ho, M.D.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNLI":"Denali Therapeutics Inc.","BK4139":"生物科技","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓"},"translate_title":"Denali Therapeutics报告第三季度净亏损1.269亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNLI":0.9},"content_text":"Denali Therapeutics reports third quarter net loss of $126.9 million\n    \n\nDenali Therapeutics Inc. reported a net loss of $126.9 million for the third quarter ended September 30, 2025, compared to a net loss of $107.2 million for the same period in 2024. Total research and development expenses were $102.0 million, up from $98.2 million in the prior year quarter, with increases driven by new operations at the company's large molecule manufacturing facility in Salt Lake City, Utah. The company highlighted continued engagement with the FDA regarding the tividenofusp alfa BLA review for MPS II and completed enrollment in the DNL126 Phase 1/2 study for MPS IIIA. Denali also submitted regulatory applications to begin clinical studies with DNL628 for Alzheimer's disease and DNL952 for Pompe disease. Leadership changes include Peter Chin, M.D., assuming the role of Acting Chief Medical Officer following the departure of Carole Ho, M.D.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001714899-25-000192), on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581017054","isCrawlerRequest":true}